Generic Name: insulin glargine
Brand Name: Semglee
Manufacturer: BGP PHARMA ULC
Therapeutic Area: Diabetes mellitus, Type 1 & 2
Indications: Diabetes mellitus, Type 1 & 2
Manufacturer Requested Reimbursement Criteria1: To be listed as the preferred insulin glargine treatment for patients who have been diagnosed with type 1 or type 2 diabetes requiring long-acting insulin.
Submission Type: Initial
Project Status: Withdrawn
Biosimilar: Yes
Companion Diagnostics: No
Fee Schedule: Schedule D
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2 | |
|---|---|
| Call for patient input posted | October 16, 2018 |
| Patient group input closed | December 04, 2018 |
| Clarification: - Patient input submission received from Diabetes Canada | |
| Patient input summary sent for review to patient input groups | December 12, 2018 |
| Patient group comments on input summary closed | December 19, 2018 |
| Clarification: - Patient input summary feedback received | |
| Submission received | November 14, 2018 |
| Submission accepted for review | November 29, 2018 |
| Clarification: - Submission was not accepted for review on 21 Nov 2018 | |
| Review initiated | November 30, 2018 |
| Clarification: - Voluntarily withdrawn by the manufacturer on 2019-Mar-05 | |